BioTech Valuation Multiples
Explore private market BioTech valuation multiples with benchmarks structured by stage and region. Updated quarterly.
BioTech
BioTech companies develop therapeutics, diagnostics and platform technologies built on biological science — from drug discovery and genomics to cell and gene therapy. Private market BioTech valuations hinge less on current revenue and more on pipeline value: clinical-trial phase, probability of regulatory approval, addressable patient population and the strength of underlying IP. Because revenue and EBITDA are often years away, EV/Sales and risk-adjusted milestone models carry more weight than EBITDA multiples at early stages.
The category spans drug developers, diagnostics, genomics and bioinformatics, and the tools and platforms that enable them. DealMatrix tracks BioTech valuation dynamics across 7 funding stages and all major global regions, so you can benchmark a deal against the right peer set.
Sector
BioTech
Health & Life Sciences
Sector tracked since
2000
25+ years of data
EV/SALES & EV/EBITDA ACROSS
6 Regions, 7 Stages
Modelled independently via proprietary econometric approach
UPDATE FREQUENCY
Quarterly
Data updates & model improvement
BioTech Valuation Multiples by Stage
As of 30 September 2025, calculated as on the DealMatrix platform
EV/EBITDA is shown from Series C onwards.
How we derive these multiples
DealMatrix multiples are derived from institutional-grade public-market index data covering ~150 GICS sub-industries across 6 regions, with quarterly history back to 2000, and adjusted for region and funding stage in a six-step model that follows the IPEV Guidelines 2025. Published benchmarks are one year old and illustrative; because IPEV 2025 prohibits static multiples for reporting periods from 1 April 2026, current quarterly data for valuation work is available on the platform.
Your region, your industry blend, the current quarter
These figures are as of 30 September 2025, one year behind the platform. On the platform you combine up to four industries and get the current quarter.
The Venionaire DealMatrix Multiples Model
DealMatrix multiples are proprietary private-market benchmarks, derived through a six-step model that translates public capital-market index comparables into private-market segments and funding stages, adjusted for macroeconomic conditions.
The model produces three components: The reported public multiple, the model-predicted multiple, and the lower bound predicted multiple averaged into the DealMatrix Composite, then adjusted for region and funding stage. The methodology follows the IPEV Guidelines 2025.
Adaptyv Biosystems Series A: Adaptyv raises $40M Series A to automate lab work for AI-designed proteins
raised
Valuation
Isomorphic Labs Series B: Isomorphic Labs raised $2.1 Billion funding to scale its AI drug design engine
raised
Valuation
CellCentric Funding: CellCentric Raises $220M for a ‘transformative’ multiple myeloma medicine
raised
Valuation
Adcendo Series C: $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
raised
Valuation
Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials
raised
Valuation
Munich-based Tubulis secures €308 million to advance antibody-drug conjugate innovation
raised
Valuation
Similar industries to explore
Valuation benchmarks differ across industries as business models, growth rates and margins vary. Explore the sectors most related to BioTech to see how their EV/Sales and EV/EBITDA multiples compare.
BioTech Valuation Multiples — FAQ
What is the average valuation multiple for BioTech companies?
As of 30 September 2025, across all regions, venture-backed BioTech companies were valued at about 4.3× to 16.3× EV/Sales, depending on the funding stage: 16.3× at Series A, 7.6× at Series C and 4.3× at Series E. EV/EBITDA was about 30.6× at Series C and 17.4× at Series E. Region-specific and current-quarter figures are available in DealMatrix.
How does the funding stage change BioTech multiples?
Multiples rise from Pre-Seed to a peak at Series A (16.3× EV/Sales for BioTech): growth is still very high while the risk investors price in has fallen. From Series B on, growth slows faster than risk falls, and multiples come down towards the level of listed companies by Series D and E. EV/EBITDA is shown from Series C onwards.
What is the difference between EV/Sales and EV/EBITDA for BioTech?
EV/Sales (enterprise value ÷ revenue) is used for high-growth BioTech companies that are not yet profitable, while EV/EBITDA (enterprise value ÷ operating profit) applies to mature, profitable ones. Early-stage companies are usually benchmarked on EV/Sales.
How are BioTech valuation multiples calculated?
Each BioTech multiple is a weighted blend of public-market index comparables, cleaned for outliers and gaps, then adjusted for macroeconomic conditions, region, and funding stage through a six-step model that follows the IPEV Guidelines 2025.
Do BioTech valuation multiples vary by region?
Yes. North America serves as the reference market and typically carries the highest multiples, while emerging markets trade at a structural discount. Region-specific figures are available in the DealMatrix platform.
How current is this BioTech data and how often is it updated?
The benchmark shown is an illustrative annual figure as of 30 September 2025. The underlying model is updated every quarter. Because the IPEV Guidelines 2025 prohibit static multiples for reporting periods from 1 April 2026, current quarterly data for valuations is available in the DealMatrix platform.